Integrum AB Class B (SE:INTEG.B)
:INTEG.B
Want to see SE:INTEG.B full AI Analyst Report?
Top Page
Integrum AB Class B
(INTEG.B)
Select Model
Select Model
Rating:48Neutral
Price Target:
kr8.00
▼(-23.08% Downside)
Action:Reiterated
Date:06/05/26
The score is held back primarily by weak financial performance—sharp profitability deterioration, a negative gross profit in 2026, and persistent operating cash burn. Technicals are only mildly supportive in the short term and remain weaker over longer timeframes, while valuation is constrained by ongoing losses (negative P/E) and no indicated dividend support.
Positive Factors
Balance sheet strength
Very low leverage reduces refinancing and solvency risk, giving management flexibility to fund clinical training, regulatory steps, or selective commercialization spending. That balance-sheet cushion supports multi-month strategic initiatives even during operating cash burn, aiding long-term continuity.
Negative Factors
Operating cash burn
Persistent negative operating cash flow signals the core business does not generate sustainable cash, forcing reliance on equity/debt raises or reserves. This constrains strategic choices, risks dilution or covenant pressure, and limits ability to invest in commercialization or clinical scale-up over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low leverage reduces refinancing and solvency risk, giving management flexibility to fund clinical training, regulatory steps, or selective commercialization spending. That balance-sheet cushion supports multi-month strategic initiatives even during operating cash burn, aiding long-term continuity.
Read all positive factors
Integrum AB Class B (INTEG.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr217.88M
Dividend YieldN/A
Average Volume (3M)674.44K
Price to Earnings (P/E)―
Beta (1Y)0.71
Revenue Growth0.31%
EPS Growth-26.18%
CountrySE
Employees36
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.94
Shares Outstanding26,027,910
10 Day Avg. Volume474,857
30 Day Avg. Volume674,441
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)1.07
Price to Sales (P/S)2.01
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.68
Revenue Forecast (FY)kr209.00M
Integrum AB Class B Business Overview & Revenue Model
Company Description
Integrum AB (publ) focuses on the research, development, and global sale of advanced bone-anchored prosthetic solutions. A core offering is the Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant system. This innovative bo...
How the Company Makes Money
Integrum makes money primarily by selling its osseointegration implant systems and associated components used in surgical procedures that enable prostheses to be attached directly to the patient’s skeleton. Revenue is generated from (1) product sa...
Integrum AB Class B Financial Statement Overview
Summary
Income Statement
27
Negative
Balance Sheet
72
Positive
Cash Flow
18
Very Negative
| Breakdown | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 91.39M | 91.10M | 104.12M | 74.27M | 55.72M |
| Gross Profit | -51.52M | 75.38M | 91.26M | 60.84M | 46.56M |
| EBITDA | -39.62M | -35.50M | 8.76M | -20.24M | 2.60M |
| Net Income | -46.34M | -30.85M | 4.03M | -16.18M | 21.27M |
Balance Sheet | |||||
| Total Assets | 203.60M | 203.25M | 164.86M | 165.17M | 180.44M |
| Cash, Cash Equivalents and Short-Term Investments | 19.06M | 39.60M | 16.90M | 41.92M | 75.34M |
| Total Debt | 3.17M | 4.84M | 6.42M | 7.92M | 580.89K |
| Total Liabilities | 31.59M | 25.38M | 22.07M | 21.64M | 20.70M |
| Stockholders Equity | 172.01M | 177.88M | 142.79M | 143.53M | 159.74M |
Cash Flow | |||||
| Free Cash Flow | -57.96M | -50.59M | -24.37M | -36.50M | -49.55M |
| Operating Cash Flow | -41.02M | -37.70M | -12.74M | -25.10M | -20.28M |
| Investing Cash Flow | -16.94M | -12.89M | -11.63M | -11.40M | -29.27M |
| Financing Cash Flow | 37.43M | 73.29M | -648.54K | 3.08M | 117.23M |
Integrum AB Class B Technical Analysis
Positive
10.40
Price Trends
7.84
Positive
8.06
Positive
11.30
Negative
Market Momentum
0.12
Negative
57.19
Neutral
37.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:INTEG.B, the sentiment is Positive. The current price of 10.4 is above the 20-day moving average (MA) of 7.99, above the 50-day MA of 7.84, and below the 200-day MA of 11.30, indicating a neutral trend. The MACD of 0.12 indicates Negative momentum. The RSI at 57.19 is Neutral, neither overbought nor oversold. The STOCH value of 37.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:INTEG.B.
Integrum AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | kr1.25B | 41.99 | 6.93% | ― | -8.92% | -8.33% | |
55 Neutral | kr361.42M | -16.97 | -27.25% | ― | -4.08% | 1.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr576.47M | -66.43 | -2.52% | ― | -19.24% | 64.78% | |
48 Neutral | kr217.88M | -4.70 | -18.55% | ― | 0.31% | -26.18% | |
47 Neutral | kr693.32M | -5.53 | -36.55% | ― | 48.53% | 17.86% | |
46 Neutral | kr279.71M | -6.83 | -104.38% | ― | 26.25% | 43.03% |
* Healthcare Sector Average
SE:INTEG.B
Integrum AB Class B
8.17
-11.08
-57.57%
SE:SEZI
Senzime AB
4.41
-0.59
-11.71%
SE:BACTI.B
Bactiguard Holding AB
16.45
-12.05
-42.28%
SE:CRAD.B
C-Rad AB Class B
36.90
2.60
7.60%
SE:ACARIX
Acarix AB
0.25
-0.01
-5.32%
SE:MNTC
Mentice AB
12.85
-2.28
-15.05%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.